By API User
Ovarian Cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO or the Company) is pleased to announce that it has received a cash refund of $1,716,580 from the Australian Government for its FY25 Research and Development (R&D) Tax Incentive claim. Following receipt of the refund, CLEO now holds a strong cash balance of ~$5.75 million as … Continued
By API User
Highlights CLEO appoints its first U.S. Key Opinion Leader, Dr Nicholas Lambrou, a leading gynaecologic oncologist and surgical specialist Dr Lambrou to support clinical advocacy, publication development, and presentation of CLEO’s technology at major U.S. scientific meetings KOL engagement represents a key U.S. market entry activity as a part of CLEO’s commercialisation strategy for its Pre … Continued
By API User
Key Highlights: EBR secured CMS approval for NTAP reimbursement for inpatient use of the WiSE CRT System, effective 1 October 2025, establishing a reimbursement pathway for the novel WiSE CRT System for Medicare inpatients CMS approval was also received for TPT reimbursement for outpatient settings, completing a comprehensive Medicare pathway across inpatient and outpatient care Case … Continued
By API User
BlinkLab Limited (ASX:BB1), a leader in AI-powered digital diagnostics, today announced that Rush University Medical Center (“Rush”) has joined the Company’s pivotal U.S. clinical study for BlinkLab Dx 1, its smartphone-based diagnostic aid for autism. Rush becomes the eighth leading institution to participate in the FDA-endorsed 510(k) trial, expanding what is set to become one … Continued
By API User
Nexsen Limited (ASX: NXN) (, a nano-biotechnology company developing an innovative point-of-care diagnostic platform, is pleased to announce the acceleration of its US market entry for its GBS Rapid Sensor and Kidney Function Diagnostics, with the appointment of an expert consultant advising the Company on its US FDA regulatory pathway. Appointment of MCRA Nexsen has … Continued
By API User
Highlights Updated U.S. insurance data identifies over ~2 million women per year1 could benefit from CLEO’s Pre-Surgical Ovarian Cancer Test Findings reinforce the unmet need and significant commercial potential for CLEO’s patented technology Data will inform a broader health economic study to support CLEO’s market entry, reimbursement and early revenue generation. ________________ MELBOURNE, AUSTRALIA, 6th November … Continued
By API User
Perth, Australia – 6 November 2025: NeuroScientific Biopharmaceuticals Limited (ASX: NSB), an innovative Australian biotechnology company developing novel technologies targeted at immune-mediated inflammatory diseases, is pleased to announce the appointment of its Clinical & Scientific Advisory Board with immediate effect. The Advisory Board will provide strategic guidance across scientific innovation, product development, clinical indications, and … Continued
By API User
Sunnyvale, California; 6 November 2025: EBR Systems, Inc. (ASX: “EBR”, “EBR Systems”, or the “Company”), developer of the world’s only wireless cardiac pacing device for heart failure, today announced that management will be participating at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 20, 2025 at The Westin Grand … Continued
By API User
Building on earlier studies showing its benefits for type 2 diabetes, a new study has revealed experimental drug ‘IC7Fc’ may also help prevent heart disease by lowering cholesterol and reducing inflammation. The international team of scientists led by Leiden University Medical Center, Netherlands, in collaboration with Monash University and others, has published a new preclinical … Continued
By API User
With ISOAPI-D, CIL offers pharmaceutical partners a secure, global supply of deuterated reagents – manufactured to the highest quality standards for faster, more efficient API development. TEWKSBURY, MASSACHUSETTS / ACCESS Newswire / October 27, 2025 / Cambridge Isotope Laboratories, Inc. (CIL), a global leader in stable isotope chemistry, announces the launch of ISOAPI-D™, a unified … Continued
